Pharmacogenomics in practice: A case report of personalized inpatient psychiatric care

Pharmacogenomics

Volumn 16, Issue 5, 2015, Pages 433-439

  Madan, Alok ^a,b   Walker, Cory R ^a,b   Weinstein, Benjamin ^a,b   Fowler, J Christopher ^a,b  

^a MENNINGER CLINIC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Inpatient psychiatry; Pharmacogenomics; Psychosis; Psychotropic medications

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE PLUS DEXAMPHETAMINE; DULOXETINE; FLUOXETINE; HYDROXYZINE; RISPERIDONE; SERTRALINE;

ADULT; ALCOHOL ABUSE; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BEDTIME DOSAGE; CANNABIS ADDICTION; CASE REPORT; CAUCASIAN; DEPRESSION; DRUG EFFICACY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MENTAL HEALTH CARE; MENTAL PATIENT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PSYCHOSIS; SUICIDAL IDEATION; TREATMENT OUTCOME; ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETICS; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHOLOGY; PSYCHOTIC DISORDERS; SINGLE NUCLEOTIDE POLYMORPHISM; TRENDS;

ADULT; ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECISION MEDICINE; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 84929085371     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.9     Document Type: Article

References (31)

1. Smits KM, Smits LJM, Schouten JSAG, Stelma FF, Nelemans P, Prins MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol. Psychiatry 9(5), 433-441 (2004)
2. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 12(3), 247-257 (2007)
3. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry 7(10), 1115-1119 (2002)
4. Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 53(1), 119-133 (2001)
5. Lencz T, Robinson DG, Napolitano B et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet. Genomics 20(9), 569-572 (2010)
6. Bhat S, Dao DT, Terrillion CE et al. CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog. Neurobiol. 99(1), 1-14 (2012)
7. Schloss P, Williams DC. The serotonin transporter: a primary target for antidepressant drugs. J. Psychopharmacol. 12(2),115-21 (1998)
8. Zhang JP, Lencz PT, Malhotra MAK. Dopamine D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am. J. Psychiatry 167(7), 763-772 (2010)
9. Cools R. Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist 14(4), 381-95 (2008)
10. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can. J. Psychiatry 52(1), 46-54 (2007)
11. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005)
12. Thase M, Rush A. When at first you don't succeed: Sequential strategies for antidepressant nonresponders. J. Clin. Psychiatry 58(13), 23-29 (1997)
13. Perlis RH, Ostacher MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry 163(2), 217-224 (2006)
14. Thase ME, Friedman ES, Biggs MM et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR D report. Am. J. Psychiatry 164(5), 739-752 (2007)
15. Thase ME, Friedman ES, Howland RH. Management of treatment-resistant depression: psychotherapeutic perspectives. J. Clin. Psychiatry 62(Suppl. 18), 18-24 (2001)
16. Boudes P. Drug compliance in therapeutic trials: a review. Control. Clin. Trials 19(3), 257-268 (1998)
17. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv. 49(2), 196-201 (1998)
18. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am. J. Psychiatry 163(11), 1905-1917 (2006)
19. American Psychiatric Association. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006. American Psychiatric Publishing, Arlington, VA, USA (2006)
20. Vogel F. Moderne probleme der Humangenetik. Ergeb. Inn. Med. Kinderheild. 12, 152-125 (1959)
21. Evans DA CC. Pharmacogenomics. Br. Med. Bull. 17, 234-240 (1961)
22. Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am. J. Psychiatry. 167(12), 1445-1455 (2010)
23. New research horizons. Science 278, 2039 (1997)
24. Clapp JD, Grubaugh AL, Allen JG et al. Modeling trajectory of depressive symptoms among psychiatric inpatients: a latent growth curve approach. J. Clin. Psychiatry 74(5), 492-499 (2013)
25. Fowler J, Madan A, Allen J et al. Improvement in healthrelated quality of life among adults with serious mental illness receiving inpatient treatment: A prospective cohort study. J. Clin. Psychiatry (2014) (In Press)
26. de Leon J. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J. Clin. Psychopharmacol. 27(3), 241-245 (2007)
27. de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 34(1), 159-172 (2009)
28. Frueh BC, Oldham JM, Fonagy P. Programmatic research at a specialty psychiatric inpatient clinic: opportunities, challenges, and future directions. Bull. Menninger. Clin. 73(4), 251-258 (2009)
29. Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA 285(5), 540-544 (2001)
30. Cappell K, Arndt M, Carey J. Drugs get smart. Business Week, 5th September (2005)
31. Hunt LM, Kreiner MJ. Pharmacogenetics in primary care: the promise of personalized medicine and the reality of racial profiling. Cult. Med. Psychiatry 37(1), 226-235 (2013).